HJF has more than 200 technologies available for licensing.

HJF supported research center participates in new study titled STORM CHASER to evaluate antibody combination therapy treatment of COVID-19.

The Wall Street Journal wrote an article about research supported by HJF to study blood-purification to treat COVID-19.

Nipah and Hendra viruses vaccine demonstrated effectiveness in preclinical studies as early as seven days following a single immunization.

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) released its FY20 annual report.

HJF received the prestigious 2021 Federal Laboratory Consortium’s (FLC) Award for Excellence in Technology Transfer.

HJF signed a cooperative agreement to support a study investigating blood filtering to treat COVID-19.

Ms. Sid Ashworth and Dr. Elder Granger have joined the Council of Directors of the Henry M. Jackson Foundation for the Advancement of Military Medicine.

HJF received approval to offer services through a GSA Multiple Award Schedule.

HJF teammate publishes research showing promising research preventing and detecting COVID-19

Two long-time HJF Council of Directors members are retiring in 2020.

GivingTuesday is a global generosity movement celebrated on the Tuesday after holiday shopping season typically begins.

HJF and Citranvi Biosciences have signed an exclusive licensing agreement to develop vaccine technologies to prevent EBV and CMV.

HJF teammate, Mario Oyola, PhD, was recently named to Cell Mentor’s list of 100 Inspiring Hispanic/Latinx Scientists in America. Oyola

HJF announced the acquisition of CAMRIS International, LLC, an international development and health research firm.